# NCAPG2 is a diagnostic biomarker associated with immune infiltration in cholangiocarcinoma

## TL;DR

NCAPG2 is a potential biomarker for diagnosing cholangiocarcinoma and is linked to immune cell activity in the tumor environment.

## Contribution

This study identifies NCAPG2 as a novel diagnostic biomarker and explores its association with immune infiltration in cholangiocarcinoma.

## Key findings

- NCAPG2 is overexpressed in cholangiocarcinoma and has diagnostic significance.
- Higher NCAPG2 levels correlate with immune cell infiltration in cholangiocarcinoma.
- NCAPG2 is functionally linked to DNA-related processes and pathological classification of CHOL.

## Abstract

Cholangiocarcinoma (CHOL) is the second largest malignant tumor in the bile duct, only after primary liver cancer. Their high invasiveness can lead to poor prognosis. Over the past decade, research on CHOL has been ongoing, but there have been no breakthrough advancements. According to the literature, NCAPG2 is associated with the progression of various tumors, but its relevant role and value in CHOL have not been extensively studied.

We studied the expression of NCAPG2 in CHOL and its clinical and pathological diagnostic value based on TCGA and GEO datasets. We evaluated the association between NCAPG2 and immune-related cells in CHOL using the TISIDB database.

We found that NCAPG2 has a higher expression level in CHOL and diagnostic significance in patients with CHOL. Additionally, we observed a correlation between immune cell infiltration and NCAPG2 levels in CHOL. Furthermore, NCAPG2 and its co-expressed genes were predominantly concentrated in ATP-dependent activity, DNA-related functions, and DNA helicase activity. The expression level of NCAPG2 is intricately linked to the pathological classification of CHOL.

Current research indicates that NCAPG2 may provide effective assistance for the early diagnosis and pathological classification of CHOL, potentially regulating the immune microenvironment and thereby influencing the occurrence and progress of CHOL.